163 related articles for article (PubMed ID: 22583459)
21. Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values.
Boland MR; van Boven JF; Kocks JW; van der Molen T; Goossens LM; Chavannes NH; Rutten-van Mölken MP
Value Health; 2015 Mar; 18(2):299-307. PubMed ID: 25773566
[TBL] [Abstract][Full Text] [Related]
22. Condition-specific preference-based measures: benefit or burden?
Versteegh MM; Leunis A; Uyl-de Groot CA; Stolk EA
Value Health; 2012 May; 15(3):504-13. PubMed ID: 22583461
[TBL] [Abstract][Full Text] [Related]
23. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
24. A comparison of techniques for eliciting patient preferences in patients with benign prostatic hyperplasia.
Schulz MW; Chen J; Woo HH; Keech M; Watson ME; Davey PJ
J Urol; 2002 Jul; 168(1):155-9. PubMed ID: 12050512
[TBL] [Abstract][Full Text] [Related]
25. QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.
Heintz E; Wiréhn AB; Peebo BB; Rosenqvist U; Levin LÅ
Value Health; 2012 May; 15(3):475-84. PubMed ID: 22583458
[TBL] [Abstract][Full Text] [Related]
26. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning.
Günther O; Roick C; Angermeyer MC; König HH
Drug Alcohol Depend; 2007 Jan; 86(2-3):253-64. PubMed ID: 16930855
[TBL] [Abstract][Full Text] [Related]
27. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
29. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
[TBL] [Abstract][Full Text] [Related]
30. The validity of EQ-5D US preference weights in liver transplant candidates and recipients.
Russell RT; Feurer ID; Wisawatapnimit P; Pinson CW
Liver Transpl; 2009 Jan; 15(1):88-95. PubMed ID: 19109831
[TBL] [Abstract][Full Text] [Related]
31. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
32. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
[TBL] [Abstract][Full Text] [Related]
33. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
[TBL] [Abstract][Full Text] [Related]
34. Italian population-based values of EQ-5D health states.
Scalone L; Cortesi PA; Ciampichini R; Belisari A; D'Angiolella LS; Cesana G; Mantovani LG
Value Health; 2013; 16(5):814-22. PubMed ID: 23947975
[TBL] [Abstract][Full Text] [Related]
35. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
[TBL] [Abstract][Full Text] [Related]
36. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
37. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility.
Buxton MJ; Lacey LA; Feagan BG; Niecko T; Miller DW; Townsend RJ
Value Health; 2007; 10(3):214-20. PubMed ID: 17532814
[TBL] [Abstract][Full Text] [Related]
38. Does the EQ-5D measure quality of life in schizophrenia?
Halling Hastrup L; Nordentoft M; Hjorthøj C; Gyrd-Hansen D
J Ment Health Policy Econ; 2011 Dec; 14(4):187-96. PubMed ID: 22345360
[TBL] [Abstract][Full Text] [Related]
39. Estimating EQ-5D utility values for major health behavioural risk factors in England.
Maheswaran H; Petrou S; Rees K; Stranges S
J Epidemiol Community Health; 2013 Feb; 67(2):172-80. PubMed ID: 22844084
[TBL] [Abstract][Full Text] [Related]
40. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia.
Wolfe F; Michaud K; Li T; Katz RS
J Rheumatol; 2010 Feb; 37(2):296-304. PubMed ID: 20032098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
